Thomas E. Boyd

3.9k citations
47 papers · 3.1k · 1 hit paper · h-index 22

Impact in

Papers in

Thomas E. Boyd

47 papers receiving 3k citations

Thomas E. Boyd's Hit Papers

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies 2012 · 959 citations
9590+4+9Years since publication250500750

Peers

Thomas E. Boyd
Comparison fields: 5 of 69
  • Genetics 1.2k
  • Pathology and Forensic Medicine 558
  • Hematology 362
  • Oncology 268
  • Pulmonary and Respiratory Medicine 276
Replace Katja Zirlik with:
Katja Zirlik Germany
Darrin M. Beaupre United States
Kathryn S. Kolibaba United States
Jeannette M. Dowell United States
Bonnie K. Harrington United States
Sarah E. M. Herman United States
Herbert Aaron Eradat United States
Stephanie R. Fink United States
Alessandra Pucciarini Italy
Shelonitda Rose United States
Thomas E. Boyd relative to Katja Zirlik Germany Katja Zirlik's profile →
Citations per field
00.5×1.7×
Katja Zirlik · 1×
Citations per year

Countries citing papers authored by Thomas E. Boyd

Since Specialization
Citations

This map shows the geographic impact of Thomas E. Boyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Boyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Boyd more than expected).

Fields of papers citing papers by Thomas E. Boyd

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Boyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Boyd. The network helps show where Thomas E. Boyd may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas E. Boyd, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas E. Boyd Line = papers co-authored together Thomas E. Boyd links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 47 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Hit paper breakdown →
2012959
2 2015294
3 2007247
4 2015222
5 2019216
6 2009141
7 2018111
8 200970
9 201868
10 201364
11 201462
12 201659
13 201959
14 201044
15 201742
16 201239
17 201539
18 200433
19 201230
20 201330

About Thomas E. Boyd

Thomas E. Boyd is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Pulmonary and Respiratory Medicine and Pharmacology, having authored 47 papers that have together received 3.1k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (25 papers), Lymphoma Diagnosis and Treatment (14 papers), Acute Myeloid Leukemia Research (6 papers), Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Diagnosis and Treatment (1 paper), Pharmacogenetics and Drug Metabolism (1 paper), Erythropoietin and Anemia Treatment (1 paper) and Testicular diseases and treatments (1 paper). The work is most often cited by research in Genetics (1.2k citations), Pathology and Forensic Medicine (558 citations), Hematology (362 citations), Oncology (268 citations) and Pulmonary and Respiratory Medicine (276 citations). Thomas E. Boyd has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Jeff Porter Sharman, Nathan Hale Fowler, Richard R. Furman, Kathryn S. Kolibaba, Sonali M. Smith, Ranjana H. Advani, Ahmed Hamdy, Barbara Grant, Joseph J. Buggy and Eric E. Hedrick. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia Research, Investigational New Drugs and The Oncologist.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact